An integrated, multidisciplinary approach for drug safety assessment

Drug Discovery Today

Volumn 9, Issue 16, 2004, Pages 687-693

  Li, Albert P ^a  

^a 21228 ^*  (United States)

Author keywords

Drug Discovery; drug safety; pharmacokinetics; Pharmacology; Toxicology; toxophore

Indexed keywords

ALOSETRON; ANALGESIC AGENT; BROMFENAC; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CISAPRIDE; DEXFENFLURAMINE; GREPAFLOXACIN; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; LEVACETYLMETHADOL; MIBEFRADIL; MONOCLONAL ANTIBODY; NEVIRAPINE; PARACETAMOL; PIOGLITAZONE; RAPACURONIUM BROMIDE; REPAGLINIDE; RISPERIDONE; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR;

ACCURACY; ACNE; ADVERSE DRUG REACTION; ANGIOGENESIS; BIOACCUMULATION; BRONCHOSPASM; CARCINOGENESIS; CARDIOTOXICITY; CELL DIVISION; CIRCULATION; CROHN DISEASE; DEFORMITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOXICITY; DRUG UPTAKE; ENZYME INDUCTION; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GASTRITIS; GENOTOXICITY; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFECTION; INFLAMMATION; IRRITABLE COLON; ISCHEMIC COLITIS; LIVER; LIVER MICROSOME; LIVER TOXICITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPIATE ADDICTION; OXYGENATION; PREGNANCY COMPLICATION; PROTEOMICS; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STROKE; VALVULAR HEART DISEASE;

EID: 4043137923     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03166-6     Document Type: Short Survey

References (22)

1. Lasser K.E., et al. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287:2002;2215-2220
2. Dimasi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:2003;151-185
3. Easterbrook J., et al. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem. Biol. Interact. 134:2001;243-249
4. Volpe D.A., et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother. Pharmacol. 39:1996;143-149
5. Borzelleca J.F. Paracelsus: herald of modern toxicology. Toxicol. Sci. 53:2000;2-4
6. Centocor Dear Health Professional Letter October 5, 2001.
7. Hulzebos E.M., Posthumus R. (Q)SARs: gatekeepers against risk on chemicals? SAR QSAR Environ. Res. 14:2003;285-316
8. Zmuidinavicius D., et al. Progress in toxinformatics: the challenge of predicting acute toxicity. Curr. Top. Med. Chem. 3:2003;1301-1314
9. MacGregor J.T., et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 59:2001;17-36
10. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today. 6:2001;357-366
11. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142:2002;7-23
12. Boelsterli U.A., et al. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit. Rev. Toxicol. 25:1995;207-235
13. Williams D.P., Park B.K. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov. Today. 8:2003;1044-1050
14. Uetrecht J. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev. 34:2002;651-665
15. Schleger C., et al. Development of an in vitro model for vascular injury with human endothelial cells. ALTEX. 44:(Suppl 3):2004;12-19
16. Li A.P., et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121:1999;17-35
17. Li W., et al. Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins. Toxicol. In Vitro. 17:2003;107-113
18. Li, A.P. (2004). A novel cell culture tool. U. S. P. T. O. application number 10/751983.
19. Kier L.D., et al. Applications of microarrays with toxicologically- relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat. Res. 549:2004;101-113
20. Schiodt F.V., et al. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment. Pharmacol. Ther. 16:2002;707-715
21. Boelsterli U.A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192:2003;307-322
22. Roth R.A., et al. Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther. 307:2003;1-8